Targeting the androgen receptor in prostate and breast cancer: Several new agents in development Journal Article
| Authors: | Proverbs-Singh, T.; Feldman, J. L.; Morris, M. J.; Autio, K. A.; Traina, T. A. |
| Article Title: | Targeting the androgen receptor in prostate and breast cancer: Several new agents in development |
| Abstract: | Prostate cancer (PCa) and breast cancer (BCa) share similarities as hormone-sensitive cancers with a wide heterogeneity of both phenotype and biology. The androgen receptor (AR) is a hormone receptor involved in both benign and malignant processes. Targeting androgen synthesis and the AR pathway has been and remains central to PCa therapy. Recently, there has been increased interest in the role of the AR in BCa development and growth, with results indicating AR co-expression with estrogen, progesterone, and human epidermal growth factor receptors, across all intrinsic subtypes of BCa. Targeting the AR axis is an evolving field with novel therapies in development which may ultimately be applicable to both tumor types. In this review, we offer an overview of available agents which target the AR axis in both PCa and BCa and provide insights into the novel drugs in development for targeting this signaling pathway. © 2015 Society for Endocrinology. |
| Keywords: | signal transduction; protein expression; unclassified drug; review; sunitinib; cancer growth; antineoplastic agent; unindexed drug; breast cancer; protein targeting; dasatinib; carcinogenesis; cancer resistance; temsirolimus; prostate cancer; androgen receptor; abiraterone acetate; bicalutamide; flutamide; nilutamide; trastuzumab; hormone receptor; castration resistant prostate cancer; molecular pathology; randomized controlled trial (topic); molecularly targeted therapy; phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); triple negative breast cancer; androgen receptor antagonist; orteronel; androgen synthesis; ganetespib; new drug; tivozanib; estrogen receptor positive breast cancer; enzalutamide; antiandrogen therapy; azd 3514; galeterone; odm 201; alisertib; buparlisib; human; male; dactolisib; ipatasertib; epidermal growth factor receptor 2 positive breast cancer; apatorsen; 4 [7 [6 cyano 5 (trifluoromethyl) 3 pyridinyl] 8 oxo 6 thioxo 5,7 diazaspiro[3.4]octan 5 yl] 2 fluoro n methylbenzamide; apitolisib; enobosarm; onalespib; vt 464 |
| Journal Title: | Endocrine-Related Cancer |
| Volume: | 22 |
| Issue: | 3 |
| ISSN: | 1351-0088 |
| Publisher: | Bioscientifica Ltd |
| Date Published: | 2015-06-01 |
| Start Page: | R87 |
| End Page: | R106 |
| Language: | English |
| DOI: | 10.1530/erc-14-0543 |
| PROVIDER: | scopus |
| PUBMED: | 25722318 |
| PMCID: | PMC4714354 |
| DOI/URL: | |
| Notes: | Export Date: 3 August 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work